Search | BIO

Home

Search

202 Results Found

Dr. Emanuel Misses the Mark with Latest Industry Attack

Writing for The Atlantic, Dr. Ezekiel Emanuel accuses the biopharmaceutical industry of being “deceptive” when it seeks to explain the cost of prescription drugs. But in making this claim, Dr. Emanuel is guilty of engaging in some of his own acts of deception. For starters, drug prices are not …

It Starts with One—Partnering Meeting Leads to Unique Public-Private Partnership

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the success of the Orphan Drug Act and highlighting the importance of preserving incentives to help spur the development of new drugs in this space. “The truth is, incentives provided by the ODA have…

Why We Need Innovation in Food and Agriculture

Two of our most beloved breakfast beverages — coffee and orange juice — are under serious threat from disease, insects and climate change. But don’t be too alarmed. Scientists are looking at innovative new ways to protect and strengthen coffee plants and citrus trees. With gene editing and the…

Close up of a doctor's hand holding a vaccine

Latest Measles Outbreak is a Crash Course on the Importance of Immunization

It’s hard to miss the news coming from the Pacific Northwest. Every major media outlet is covering the latest measles outbreak. Social media feeds are loaded with real-time data as the virus continues to spread. And the state of Washington has officially declared a State of Emergency. In case the…

Trump Administration Should Remain Steadfast in Pushing China Towards Structural Reforms

As part of the 90-day trade negotiations between the United States and China, today Chinese Vice Premier Liu He is in Washington to participate in bilateral trade talks with the Trump administration. One major component the Trump administration has pushed for in such trade talks is structural…

Greenwood Shines Spotlight on Insurance Industry Rip-off

Writing for The Hill, BIO’s President and CEO Jim Greenwood shined a spotlight on a shocking Wall Street Journal investigation showing how health insurance companies in the U.S. dramatically inflated their cost projections under Medicare Part D for financial gain over a 10 year period: “Under…

The Right Way to Address Prescription Drug Costs

Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City Capital’s David Beier to outline for policymakers the best approach for tackling the affordability of prescription drugs. “As policy professionals from different sides of the aisle, we believe there is a right way…

Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio

During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks Radio, for a discussion about innovation taking place in the biopharma industry, the cost and value of prescription medicines and how the recent midterm elections may impact the drug pricing debate…

Greenwood Highlights Role of Innovation in Solving Opioid Crisis

The numbers are staggering. The opioid epidemic is costing our nation more than $500 billion annually in health and social costs. What’s more, 1 in 5 deaths among young adults in 2016 were opioid related. This crisis is plaguing communities across the country, leaving in its wake countless victims,…

Senate Has the Power to Expand Access to Medication for Opioid Addiction

BIO President and CEO Jim Greenwood posted the following op-ed on Linked-In today, making the case for the U.S. Senate to act on legislation that would empower the Centers for Medicaid and Medicare Services to broaden coverage of medication-assisted treatment to help Americans in the throes of…